Skip to main content

Anti-HIV-1 ADCC: clinical and therapeutic implications.

Publication ,  Journal Article
Weinhold, KJ
Published in: Biotechnol Ther
1991

The predominant antienvelope cell-mediated cytotoxicity in HIV-1-infected patients is a direct form of antibody-dependent cellular cytotoxicity (ADCC) in which circulating NK/K cells armed with cytophilic antibodies comprise a cytolytic effector cell complex capable of destroying HIV-1-expressing targets. This non-MHC-restricted form of virus-specific cytotoxicity is present in most infected patients, with maximum activity in early disease, gradually declining with disease progression. This endogenous cytotoxicity provides a focal point in the design of interventive strategies involving immune-based therapies. In the first such attempts, the lymphokine interleukin-2 has been employed in an effort to augment these potentially beneficial cytolytic reactivities. The focus of this article is to present the rationale, early clinical results, and future direction of such therapeutic approaches and, in doing so, to illustrate how careful basic research findings can be applied to the design of rational therapeutic strategies.

Duke Scholars

Published In

Biotechnol Ther

ISSN

0898-2848

Publication Date

1991

Volume

2

Issue

1-2

Start / End Page

147 / 157

Location

United States

Related Subject Headings

  • Killer Cells, Natural
  • Immunotherapy
  • Humans
  • HIV-1
  • HIV Infections
  • Antibody-Dependent Cell Cytotoxicity
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Weinhold, K. J. (1991). Anti-HIV-1 ADCC: clinical and therapeutic implications. Biotechnol Ther, 2(1–2), 147–157.
Weinhold, K. J. “Anti-HIV-1 ADCC: clinical and therapeutic implications.Biotechnol Ther 2, no. 1–2 (1991): 147–57.
Weinhold KJ. Anti-HIV-1 ADCC: clinical and therapeutic implications. Biotechnol Ther. 1991;2(1–2):147–57.
Weinhold, K. J. “Anti-HIV-1 ADCC: clinical and therapeutic implications.Biotechnol Ther, vol. 2, no. 1–2, 1991, pp. 147–57.
Weinhold KJ. Anti-HIV-1 ADCC: clinical and therapeutic implications. Biotechnol Ther. 1991;2(1–2):147–157.

Published In

Biotechnol Ther

ISSN

0898-2848

Publication Date

1991

Volume

2

Issue

1-2

Start / End Page

147 / 157

Location

United States

Related Subject Headings

  • Killer Cells, Natural
  • Immunotherapy
  • Humans
  • HIV-1
  • HIV Infections
  • Antibody-Dependent Cell Cytotoxicity